M6123 / Ligand, EMD Serono - LARVOL DELTA

FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. (PubMed, Eur J Cancer) - "Finally, NSCLC PDX models demonstrating FGFR1 amplification and FGFR1 protein overexpression were sensitive to M6123. The unique molecular and immune features of tumours with high FGFR1 expression provide a rationale to stratify patients in future clinical trials of FGFR1 pathway-targeting agents."

IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • KRAS • PD-L1

A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates. (PubMed, Toxicol Appl Pharmacol) - "These effects in monkeys are likely related to the enhanced ADCC activity of M6123. Overall, M6123 showed a superior safety profile in animals compared to bivalent FGFR1 antagonists or pan-FGFR inhibitors."

Journal • Metabolic Disorders • Nephrology • Oncology • FGF • FGFR1

[VIRTUAL] M6123, a selective FGFR1 antagonist, demonstrates anti-tumor activity as monotherapy and in combination with chemotherapy in mesothelioma models (AACR-II 2020) - "Despite the poor prognosis and increasing incidence of this disease, the combination of pemetrexed with cisplatin currently remains the only available treatment option to patients. In summary, M6123 showed favorable anti-tumor activity in preclinical models of mesothelioma, in particular in combination with standard of care chemotherapy. Further preclinical testing is warranted to confirm a predictive biomarker signature for selection of mesothelioma patients that may benefit from addition of M6123."

Combination therapy • Monotherapy • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • Thoracic Cancer • FGFR1